HBA1C, Weight, and Other Factors Through Interven-tion with Exenatide Once Weekly (DURATION)-5 was arandomized, open-label trial comparing the safety and ef-ficacy of ExQW and ExBID, both provided in their (in-tended) commercial forms, over 24 wk in patients withtype 2 diabetes treated with diet and exercise alone or incombination with a single or multiple oral antidiabeticagents. Patients and Methods Patients Randomized patients (n /H11005254) were at least 18 yr of age and diagnosed with type 2 diabetes, otherwise healthy, and treatedfor at least 2 months with diet and exercise alone or with a stable,maximally effective regimen of metformin, sulfonylurea (SU),thiazolidinedione, or a combination of these medications. Ad-ditional entry criteria included an HbA1c of 7.1–11.0%, fastingplasma glucose (FPG) concentration less than 280 mg/dl (15.5mmol/liter), and a body mass index of 25–45 kg/m 2. Patients